Small cell lung carcinoma (SCLC) accounts for 15% of all lung cancers and is the most aggressive lung cancer type. It is of neuroendocrine origin with a very strong association with smoking. It typically presents as a large central/hilar mass, and at diagnosis, 60-70% of patients have extensive disease. With a volume doubling time of 25-30 days, it is the fastest-growing lung cancer. SVC syndrome and paraneoplastic syndromes (SIADH, Cushing, Lambert-Eaton) are common. Classified into two stages: limited and extensive. Highly sensitive to chemotherapy but relapse is nearly inevitable. Five-year survival is 15-25% in limited stage and less than 2% in extensive stage.
Age Range
50-80
Peak Age
65
Gender
Male predominant
Prevalence
Uncommon
Small cell carcinoma originates from neuroendocrine (Kulchitsky) cells in the bronchial mucosa. These cells are part of the APUD (Amine Precursor Uptake and Decarboxylation) system and can secrete various hormones (ACTH, ADH, serotonin) — forming the basis of paraneoplastic syndromes. Tumor cells are very small (lymphocyte-sized) with a high mitotic index — the reason for incredibly rapid growth. Due to central location and early lymphangitic/hematogenous spread, massive mediastinal/hilar lymphadenopathy is usually present at diagnosis. On CT, it appears as a large, lobulated hilar/mediastinal mass — the mass is often inseparable from lymphadenopathy creating an 'iceberg' appearance. Rapid growth compresses blood vessels and may cause SVC syndrome. Cavitation is extremely rare because tumor cells proliferate so rapidly that necrotic spaces fill before they can form.
The inseparable conglomerate formation of the central/hilar mass with massive mediastinal lymphadenopathy is the signature finding of small cell carcinoma. The tumor fills the mediastinum like the underwater portion of a large iceberg — the hilar primary mass is only the visible small part, the true tumor burden is in the much larger mediastinal component. Homogeneous enhancement and absence of cavitation complete this 'iceberg' appearance. This finding combination, especially in patients with heavy smoking history and rapid symptom development, suggests small cell carcinoma with high confidence.
Large central/hilar mass + massive mediastinal lymphadenopathy: Mass is typically 5-10 cm, lobulated, forming a conglomerate with hilar and mediastinal lymph nodes. Primary mass and LAP are usually inseparable — 'iceberg' appearance. Subcarinal, paratracheal, and aortopulmonary window lymph nodes are frequently involved. Homogeneous or mildly heterogeneous enhancement.
Report Sentence
A large ___ cm mass in the right/left hilum with bilateral mediastinal lymphadenopathy is identified, with the primary mass inseparable from lymphadenopathy; small cell lung carcinoma should be the primary consideration.
SVC compression/invasion: Large mediastinal mass or paratracheal lymphadenopathy compresses or invades the SVC. Narrowing or occlusion of SVC lumen, filling defect in SVC wall (tumor thrombus), collateral circulation in mediastinal/chest wall/neck veins. SVC syndrome occurs in 3-5% of all lung cancers, 50-65% of which are SCLC.
Report Sentence
The mediastinal mass/lymphadenopathy is compressing/invading the SVC with significant narrowing of the SVC lumen and mediastinal/chest wall collateral venous circulation; consistent with SVC syndrome.
Absence of cavitation: Despite large mass, cavitation is extremely rare (2-5%). This is one of the key distinguishing features from squamous cell carcinoma. Mass shows homogeneous or mildly heterogeneous attenuation. Significant necrosis may only be seen post-treatment.
Report Sentence
The large central mass does not demonstrate cavitation with relatively homogeneous attenuation; this finding is consistent with small cell lung carcinoma.
Very high FDG uptake on PET-CT: SUVmax typically >10, often ranging 15-30. Demonstrates the highest FDG uptake among all lung cancer types. Critical for extensive stage staging — screening for brain, bone, liver, adrenal metastases. Also important for treatment response assessment.
Report Sentence
The hilar/mediastinal mass and lymphadenopathy demonstrate very intense FDG uptake on PET-CT (SUVmax: ___); consistent with small cell lung carcinoma. Brain MRI and whole-body staging are recommended for extensive disease evaluation.
Marked diffusion restriction on MRI DWI: Due to very high cellularity, markedly high DWI signal and very low ADC value (<0.8 × 10⁻³ mm²/s). MRI is superior to CT for brain metastasis screening — small metastases showing diffusion restriction may be missed on CT.
Report Sentence
The mass demonstrates marked diffusion restriction on MRI DWI (ADC: ___ × 10⁻³ mm²/s) consistent with very high cellularity; small cell carcinoma should be considered.
Distant metastases: Present in 60-70% of patients at diagnosis. Most common metastatic sites: brain (30-50%), liver (25-35%), bone (20-30%), adrenal (15-20%), contralateral lung. Liver metastases appear as hypodense lesions, bone metastases as lytic lesions, adrenal metastases as bilaterally enlarged adrenal glands.
Report Sentence
In addition to the primary lung tumor, findings consistent with liver/bone/adrenal/brain metastases are identified, and extensive-stage small cell lung carcinoma should be considered.
Criteria
Tumor confined to one hemithorax + ipsilateral mediastinal/supraclavicular lymph nodes. Can be included in a single radiation field. 30-40% of patients.
Distinct Features
Unilateral hilar mass + ipsilateral mediastinal LAP on CT. No distant metastases. Concurrent chemoradiation + prophylactic cranial irradiation. 5-year survival 15-25%. Complete response rate 50-70%.
Criteria
Spread beyond one hemithorax: contralateral lung/lymph nodes, pleural effusion, pericardial effusion, or distant metastases. 60-70% of patients.
Distinct Features
Bilateral disease, pleural effusion, distant organ metastases on CT. Chemotherapy + immunotherapy (atezolizumab). Median survival 10-12 months. Complete response rate 15-20%.
Criteria
Small cell carcinoma + NSCLC component (adenocarcinoma/squamous cell/large cell). 5-10% of patients.
Distinct Features
May be indistinguishable from pure SCLC on imaging. Diagnosis is histopathological. Prognosis similar to pure SCLC. Treatment follows SCLC protocol.
Distinguishing Feature
Squamous cell carcinoma can be central but cavitation is frequent (30-80%), lymphadenopathy is less massive, and primary mass is usually separable from LAP. In SCLC, cavitation is very rare, LAP is massive, and mass is inseparable from LAP.
Distinguishing Feature
Lymphoma may present with mediastinal lymphadenopathy but usually without a primary lung mass. Anterior mediastinal location is common (Hodgkin). Younger age group. In SCLC, the combination of central hilar mass + LAP and heavy smoking history is distinguishing.
Distinguishing Feature
Carcinoid tumor can be central/endobronchial but shows much slower growth, size typically <3 cm, marked enhancement (hypervascular), calcification (30%). No massive LAP. SCLC is much larger, faster growing, and accompanied by massive LAP.
Urgency
emergentManagement
medicalBiopsy
NeededFollow-up
specialist-referralSmall cell carcinoma is an oncological emergency — treatment should not be delayed due to rapid growth. SVC syndrome may require emergency radiation or stenting. Surgery has a very limited role (only stage I, rare). Concurrent platinum-etoposide chemotherapy + thoracic radiation + prophylactic cranial irradiation is standard for limited stage. Platinum-etoposide + immunotherapy (atezolizumab/durvalumab) is the standard first line for extensive stage. Initially very sensitive to chemotherapy (60-80% response) but relapse is nearly inevitable. PCI (prophylactic cranial irradiation) is used for brain metastasis prophylaxis. Multidisciplinary approach is mandatory.
SCLC is highly chemosensitive but has high recurrence rates. Limited stage disease is treated with chemoradiation, extensive stage with chemotherapy + immunotherapy. Prophylactic cranial irradiation should be considered.